Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jennifer S. Temel"'
Autor:
Rebecca S. Heist, Alice T. Shaw, Alona Muzikansky, Meghan Campo, Jennifer S. Temel, Jeffrey A. Engelman, David E. Gerber, Justin F. Gainor, Panos Fidias, Lecia V. Sequist
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 11(11)
Objectives The mechanisms of acquired resistance to the irreversible EGFR inhibitor afatinib are not well documented. We performed this prospective clinical trial to determine the prevalence of the mutation T790M in afatinib-resistant patients. Metho
Autor:
Patricia O. McCarthy, Jeffrey Settleman, Alona Muzikansky, Jennifer S. Temel, Panos Fidias, Alice T. Shaw, Sreenath V. Sharma, Thomas J. Lynch, Subba R. Digumarthy, Jeffrey G. Supko, Lecia V. Sequist, Joel W. Neal, Sarah B. Goldberg, Rebecca S. Heist
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(10)
Introduction This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non–small-cell lung cancer. Methods
Autor:
Tony Reiman, Lee M. Krug, Geoffrey I. Shapiro, Jeffrey Crawford, Daniel C. Adelman, David R. Spigel, Glenn Michelson, Donald Y. Young, Jennifer S. Temel, Ute Hoch, David S. Ettinger
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(2)
Introduction: Voreloxin is an anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, causing double-strand breaks in DNA, irreversible G2 arrest, and rapid onset of apoptosis. Based on preclinical activity of voreloxin i
Autor:
Rebecca S. Heist, Jennifer S. Temel, Lance Leopold, Waseem Khan, Jerry Fain, Lecia V. Sequist, Panos Fidias, Valari Brainerd, Julian R. Molina, Thomas J. Lynch, Bernard Chinnasami
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 5(10)
Introduction: AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC. Methods: An
Autor:
Joseph A. Greer, Jennifer S. Temel, Matthew R. Smith, Thomas J. Lynch, Paula Downes Vogel, David C. Christiani, William F. Pirl, Michael B. Sullivan, Sarah B. Goldberg
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(5)
Introduction: Exercise improves functional outcome and symptoms for certain cancer populations, but the feasibility, efficacy, and safety of structured exercise in patients with lung cancer is unknown. In this study, we examined the feasibility of a
Autor:
Jennifer S, Temel, William F, Pirl, Christopher J, Recklitis, Barbara, Cashavelly, Thomas J, Lynch
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(5)
Fatigue is one of the most common symptoms in patients with advanced cancers. Despite its high prevalence, it is often unrecognized and undetected. This study assessed the feasibility and validity of a one-item fatigue scale (OIFS) in an outpatient o